Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 8/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838277 | 0.93 | THRB (0.34) | TYMPTHRBPOLBP2RY6P2RY14 | |
| SCHEMBL13134715 | 0.90 | TYMP (0.40) | TYMPTHRBPOLBP2RY6P2RY14 | |
| SCHEMBL2814951 | 0.90 | ABL1 (0.39) | TYMPTHRBPOLBP2RY6P2RY14 | |
| SCHEMBL416716 | 0.90 | TYMP (0.39) | TYMPPOLBP2RY6P2RY14P2RY2 | |
| SCHEMBL2816613 | 0.88 | TYMP (0.41) | TYMPTHRBNT5ESLC6A1SLC6A11 | |
| SCHEMBL2816616 | 0.88 | TYMP (0.41) | TYMPTHRBNT5ESLC6A1SLC6A11 | |
| SCHEMBL12449768 | 0.88 | TYMP (0.43) | TYMPPOLBP2RY6P2RY14P2RY2 | |
| SCHEMBL13134717 | 0.86 | THRB (0.33) | TYMPTHRBPOLBP2RY6P2RY14 | |
| SCHEMBL2812686 | 0.83 | THRB (0.35) | TYMPTHRBPOLBP2RY6P2RY14 | |
| SCHEMBL13134725 | 0.83 | THRB (0.35) | TYMPTHRBPOLBP2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623104-A1 | Substituted nucleoside and nucleotide analogs | Alios Biopharma, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249068-A1 | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGS | PNP, TYMP, NTPCR | TYMP 2/4885THRB 3293/4885POLB 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.